Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations.
Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations.
复制标题
DOI：
10.18632/oncotarget.22430
复制
发表时间：
2017-12-12
期刊：
影响因子：
--
通讯作者：
Chung JH
中科院分区：
文献类型：
--
作者：
Hahn SY;Kim TH;Ki CS;Kim SW;Ahn S;Shin JH;Chung JH
本研究旨在探讨端粒酶逆转录酶（TERT）启动子或原癌基因 BRAF 突变与超声（US）和甲状腺乳头状癌（PTC）的临床病理特征之间是否存在任何关系。该研究纳入了1994年10月至2004年12月期间经手术确诊的150例PTC患者。根据TERT启动子或BRAF突变的存在，我们将患者分为三组（无突变、仅BRAF突变或TERT+BRAF突变），并分析了TERT启动子或BRAF突变与超声和临床病理特征之间的关系。根据突变分析估计复发率或死亡率。无突变35例（23.3%），仅BRAF突变104例（69.3%），TERT+BRAF突变11例（7.3%）。随着基因突变数量从无突变增加到仅 BRAF 突变再到 BRAF 和 TERT 突变，低回声、非平行方向、毛刺/微分叶边缘、微钙化和高度怀疑类别的比例增加。具有 TERT+BRAF 突变的 PTC 比其他组复发的频率更高（奇数比 = 17.921 和 31.468）。 TERT+BRAF 突变组的复发间隔和总生存期显着短于其他组 (Ps <.0001)。无突变、仅具有 BRAF 突变以及同时具有 TERT 和 BRAF 突变的 PTC 表现出恶性超声特征的概率呈线性增加。在 PTC 中，与单独的 BRAF 突变相比，BRAF 与 TERT 突变共存与复发和死亡率的相关性更强。
This study is to investigate if any relationship exists between the telomerase reverse transcriptase (TERT) promoter or proto-oncogene BRAF mutation and ultrasound (US) and clinicopathological features of papillary thyroid carcinomas (PTCs). The study included 150 patients with surgically confirmed PTC from October 1994 to December 2004. According to the existence of TERT promoter or BRAF mutations, we categorized patients into three groups (no mutation, BRAF mutation alone, or TERT+BRAF mutations) and analyzed the relationships between TERT promoter or BRAF mutation and US and clinicopathological features. The rate of recurrence or death according to mutation analysis was estimated. There were 35 (23.3%) cases with no mutation, 104 (69.3%) with BRAF mutation alone, and 11 (7.3%) with TERT+BRAF mutations. As the number of genetic mutations increased from no mutation to BRAF mutation alone to both BRAF and TERT mutations, the proportions of hypoechogenicity, non-parallel orientation, spiculated/microlobulated margin, microcalcifications, and high suspicion category increased. PTCs with TERT+BRAF mutations recurred more frequently than other groups (odd ratio = 17.921 and 31.468). The intervals to recurrence and overall survival were significantly shorter in the TERT+BRAF mutation group than in the other groups (Ps <.0001). PTCs with no mutation, with BRAF mutation alone, and with both TERT and BRAF mutations linearly increase in the probability of displaying malignant US features. In PTCs, the coexistence of BRAF with TERT mutations is more strongly correlated with recurrence and mortality than BRAF mutation alone.
登录
查看更多内容
影响因子：
3.2
作者：
Chng, Chiaw-Ling;Kurzawinski, Tom R.;Beale, Tim
通讯作者：
Beale, Tim
甲状腺细针运动活检中的诊断和预后启动子突变。
影响因子：
3.9
作者：
Liu R;Xing M
通讯作者：
Xing M
影响因子：
--
作者：
Jin L;Chen E;Dong S;Cai Y;Zhang X;Zhou Y;Zeng R;Yang F;Pan C;Liu Y;Wu W;Xing M;Zhang X;Wang O
通讯作者：
Wang O
影响因子：
5.9
作者：
MAZZAFERRI, EL;JHIANG, SM
通讯作者：
JHIANG, SM
影响因子：
--
作者：
Palme, CE;Waseem, Z;Freeman, JL
通讯作者：
Freeman, JL